ABOUT US

OUR TEAM

  • Chief Investment Officer at Versa Capital Management, LLC
  • Over 25 years experience in Private Equity and Investment
  • J.D. from Stanford Law School (with distinction, law review, Order of the Coif)
Paul Halpern, J.D.
Founder, CEO and Managing Member
  • Scientific Founder of Immunome (NASDAQ:IMNM)
  • Joseph and Ray Gordon Chair in Clinical Oncology and Research at the Lankenau Medical Center in Wynnewood, PA
  • Yale M.D., Ph.D., with post-grad medical training at Dana Farber/Partners Cancer Care and the Whitehead Institute
Scott Dessain, M.D., Ph.D.
Founder and Chief Scientific Officer
  • Managed internal antibody discovery for Immunome; expertise in drug development and portfolio management
  • Developed assets for and contributed to strategic collaborations valued in excess of $3B
  • Duke Ph.D. with Presidential postdoc fellowship at Novartis
Pavel Nikitin, Ph.D.
Chief Development Officer
  • Onne Ganel has spent two decades in the healthcare technology field
  • Led acquisitions in excess of $500m in total value on behalf of Fortune 500 companies, and commercializing technologies across the healthcare spectrum
Onne Ganel, MBA
Business Development
  • Decorated Marine; expertise in strategic planning and project management
  • B.S. in neuroscience and philosophy from Vanderbilt University
Thomas Halpern, Capt USMC
Chief Operating Officer
  • Immunologist with over 18 years of experience and co-inventor of the OCMS technology
  • Responsible for the discovery of numerous critical antibodies, including the new international potency standard for inactivated poliovirus vaccines (IPV).
Rama Devudu Puligedda, PhD
Director of Immunology

Scientific Advisory Board

  • Diabetes, Obesity, and Metabolism KOL
  • Studies the molecular control of metabolism
  • Director of the Rodent Metabolic Phenotyping Core at Penn
Paul M. Titchenell, Ph.D.
Associate Professor, Physiology at Penn
  • RSV, Immunology and Infectious Diseases KOL
  • Clinical pediatric lead, oversees difficult-to-treat infections at U Hospital Southhampton
  • Director of the Southampton NIHR Clinical Research
Saul N. Faust, MBBS, FRCPCH, PhD, FHEA, OBE

Professor, Pediatric Immunology & Infect at UHS

  • Independent Biopharma Strategy Consultant
  • SVP, Strategic Planning, Sudler & Hennessey
  • Various marketing positions at Bristol-Myers Squibb, Amgen, Merck
Daniela Matson
Targets & Indication
Scroll to Top